MediciNova, Inc. (MNOV)
$
1.42
Key metrics
Financial statements
Free cash flow per share
-0.2170
Market cap
68.2 Million
Price to sales ratio
0
Debt to equity
0.0037
Current ratio
13.8806
Income quality
0.9632
Average inventory
0
ROE
-0.2071
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
MediciNova, Inc., a biopharmaceutical company incorporated in 2000 and headquartered in La Jolla, California, focuses on developing novel small molecule therapeutics aimed at treating significant diseases with unmet medical needs in the United States. The company's product pipeline includes MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent designed for neurological disorders such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. In addition, MediciNova is developing other therapeutics like MN-221 (bedoradrine), which targets acute exacerbations of asthma and is a selective beta-2-adrenergic receptor agonist. Another promising compound, MN-001 (tipelukast), is an orally bioavailable small molecule aimed at treating fibrotic diseases like nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis, while MN-029 (denibulin) acts as a tubulin binding agent for treating solid tumor cancers. The gross profit ratio is 0.00 reflecting the efficiency of the company's production and sales operations. Additionally, the company reported depreciation and amortization expenses of $21,077.00 showcasing the wear and tear of its assets. The operating income ratio is 0.00 indicating the company's operational profitability margin, while selling, general, and administrative expenses amounted to $5,480,600.00 revealing its operational overhead costs. The EBITDA ratio stands at 0.00 highlighting the company's operational efficiency. In the financial landscape, the stock is affordable at $1.42 making it suitable for budget-conscious investors. However, this stock has a low average trading volume of 12,988.00 indicating lower market activity, which may appeal to a specific investor profile. With a market capitalization of $69,645,604.00 the company is classified as a small-cap player, representing a unique segment of potential growth. MediciNova is a key player in the Biotechnology industry, contributing significantly to the overall market landscape and driving innovation. Furthermore, it belongs to the Healthcare sector, which is essential for fostering development and expansion within the biopharmaceutical field.
Is MediciNova, Inc. (MNOV) a good investment?
Investing in MediciNova, Inc. (MNOV) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
What is MediciNova, Inc. (MNOV)'s stock forecast?
Analysts predict MediciNova, Inc. stock to fluctuate between $1.12 (low) and $2.55 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is MediciNova, Inc.'s market capitalization?
As of 2025-05-29, MediciNova, Inc.'s market cap is $69,645,604, based on 49,046,200 outstanding shares.
How does MediciNova, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., MediciNova, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy MediciNova, Inc. (MNOV) stock?
To buy MediciNova, Inc. (MNOV) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for MNOV. Place an order (Market, Limit, etc.).
What is the best time to invest in MediciNova, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did MediciNova, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$0.23 | Growth: 35.29%.
Where can I find MediciNova, Inc.'s investor relations reports?
Visit https://www.medicinova.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for MediciNova, Inc.?
You can explore historical data from here
What is the all-time high and low for MediciNova, Inc. stock?
All-time high: $10.81 (2021-03-10) | All-time low: $1.12 (2024-08-12).
What are the key trends affecting MediciNova, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
2 months ago
LA JOLLA, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announces that their CEO, Yuichi Iwaki, MD, Ph.D., and CBO, David H. Crean, Ph.D., will be participating in investor meetings at D. Boral Capital's, Inaugural DBC Conference on May 14, 2025 at the Plaza Hotel, New York City. The conference will bring together public and private executives with institutional investors, high-net worth individuals, and corporate clients from various sectors including Healthcare & Life Sciences. Drs. Iwaki and Crean will be discussing MediciNova's leading programs in neurologic and metabologic disorders. For more information about participation in the DBC Conference, visit https://dboralcapital.com/conference .
globenewswire.com
2 months ago
LA JOLLA, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced enrollment of the first patient in the NIH-funded Expanded Access Program (EAP) trial to evaluate MN-166 (ibudilast) in patients with Amyotrophic Lateral Sclerosis (ALS).
globenewswire.com
6 months ago
LA JOLLA, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announces the study update and interim analysis results from the Company's COMBAT-ALS Phase 2b/3 clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) will be presented at the 35th International Symposium on ALS/MND held December 6-8, 2024 in Montreal, Canada.
globenewswire.com
7 months ago
LA JOLLA, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a pending patent application for MN-001 (Tipelukast) to cover "Method to Decrease Triglyceride Synthesis in a Liver of a Subject." The allowed claims cover a groundbreaking method for decreasing triglyceride synthesis in the liver by administering MN-001 (Tipelukast) or its metabolite or pharmaceutically acceptable salt. This method is particularly beneficial for subjects diagnosed with insulin resistance, pre-diabetes, or diabetes. Once issued, this patent is expected to expire no earlier than May 26, 2042.
globenewswire.com
7 months ago
LA JOLLA, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it was notified by Sanofi that the Sanofi/Novartis litigation was settled. Accordingly, MediciNova is entitled to receive a certain amount of monetary damages through this settlement. Further details will be provided as they become available.
globenewswire.com
7 months ago
LA JOLLA, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the lead Principal Investigator of this clinical trial, Björn Oskarsson, MD, FAAN presented the update of an ongoing Phase 2/3 clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) patients at the 2024 Annual NEALS Meeting being held virtually on Oct 21-24, 2024.
globenewswire.com
8 months ago
LA JOLLA, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the National Institutes of Health (NIH) - Neurological Disorders and Stroke (NINDS) has awarded $22 million for an intermediate size Expanded Access Protocol (EAP) to evaluate the efficacy of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)1,2.
globenewswire.com
9 months ago
LA JOLLA, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding a clinical trial of MN-166 (ibudilast) in the treatment of Amyotrophic Lateral Sclerosis (ALS), COMBAT-ALS study has been selected for a poster presentation at the 35th International Symposium on ALS / MND to be held December 6-8, 2024 in Montreal, Canada. The poster presentation will be presented by lead Principal Investigator of this clinical trial, Björn Oskarsson, MD, FAAN Associate Professor of Neurology at Jacksonville, FL, Director of ALS, Center of Excellence.
globenewswire.com
9 months ago
LA JOLLA, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract was accepted for presentation regarding a clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS), COMBAT-ALS Phase 2b/ 3 study at the 2024 Annual NEALS Meeting to be held October 21-24, 2024 (a hybrid meeting in Clearwater, Florida and Online). The presentation will be in poster format and be presented by lead Principal Investigator of the clinical trial, Björn Oskarsson, MD, FAAN, Associate Professor of Neurology at Jacksonville, FL and Director, ALS Center of Excellence.
globenewswire.com
9 months ago
LA JOLLA, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application, which covers MN-166 (ibudilast) for post-COVID conditions. The Method of Use patent covers administering a therapeutically effective doses of ibudilast (or a pharmaceutically acceptable salt thereof) to alleviate a range of post-COVID conditions including anxiety, fatigue, depression, shortness of breath, post-traumatic stress disorder, chest tightness, palpitations, smell or taste dysfunction, sleep difficulties, hair loss, and rash.
See all news
